{
  "symbol": "VEEV",
  "company": "Veeva Systems Inc.",
  "generated_at": "2026-06-24T07:36:54.156Z",
  "event_count": 19,
  "events": [
    {
      "type": "pipeline_event",
      "ts": "2026-06-18T22:15:13.564Z",
      "stage": "analyst",
      "outcome": "skip",
      "reason": "Score of 39 falls below the 45-point threshold for publication or paper-tracking. The dossier shows zero insider buying, bearish options flow, and deeply oversold technicals that outweigh the compelling valuation and catalyst scores. Without smart-money confirmation or a clear income structure setup that meets the bar, this dossier is skipped.",
      "trigger": "[8k_recent] 1 recent 8-K(s) in last 7 days, latest filed 2026-06-18",
      "source": "hunter"
    },
    {
      "type": "analyst_decision",
      "ts": "2026-06-18T22:15:13.546Z",
      "skip": true,
      "reason": "Score of 39 falls below the 45-point threshold for publication or paper-tracking. The dossier shows zero insider buying, bearish options flow, and deeply oversold technicals that outweigh the compelling valuation and catalyst scores. Without smart-money confirmation or a clear income structure setup that meets the bar, this dossier is skipped.",
      "score": 39,
      "breakdown": {
        "smart_money": 0,
        "options_flow": 0,
        "catalyst": 20,
        "mispricing": 14,
        "quality": 5,
        "technical": 0
      },
      "debug_path": "drafts/2026-06-18-VEEV.analyst.debug.json"
    },
    {
      "type": "scout_dossier",
      "ts": "2026-06-18T22:14:32.270Z",
      "summary": "Veeva has experienced a brutal -49% YTD drawdown from ~$298 to $153, driven by sector rotation out of high-multiple growth software, concerns about CRM market saturation, and slow AI monetization timelines — not fundamental deterioration. The company delivered Q1 FY27 EPS of $2.24 vs. $2.135 estimate (+4.9%) and guided solid Q2. It has a net cash position of ~$7.2B (net cash/EBITDA well above 10x), zero debt, 75% gross margins, consistent positive earnings surprises across the last 8 quarters, and new AI platform wins from Merck KGaA, Teva, Kindeva, plus a UCB Safety Suite deal in June. The analyst consensus target of $245 implies ~60% upside — the stock is deeply discounted relative to peers on forward P/E (15.3x vs healthcare software sector median ~25-30x) and EV/EBITDA (18.8x). No insider open-market purchases exist; all 4 filings from June were routine RSU vesting exercises (code M), not directional bets by executives. Options flow is bearish with a whale put block at $210 strike OTM, but that's more likely hedging than directional conviction. The technical picture is deeply oversold — below both the 50 and 200 DMAs, RSI at 37.9 approaching oversold territory, and MACD still in bearish mode (histogram -1.93).",
      "verdict": "range_bound_or_income",
      "confidence": 5,
      "tool_calls": 21,
      "walltime_min": 18,
      "debug_path": "dossiers/2026-06-18-VEEV.scout.debug.json"
    },
    {
      "type": "analyst_decision",
      "ts": "2026-06-08T20:32:24.653Z",
      "skip": true,
      "reason": "Score falls well below the publication threshold due to zero smart-money conviction, mixed technicals (below 200DMA), and valuation compression driven by macro rotation rather than a specific re-rating catalyst. While elevated IV supports income structures, the dossier lacks the directional edge and catalyst timing required for a publishable thesis.",
      "score": 28,
      "breakdown": {
        "smart_money": 0,
        "options_flow": 1,
        "catalyst": 15,
        "mispricing": 5,
        "quality": 5,
        "technical": 3
      },
      "debug_path": "drafts/2026-06-08-VEEV.analyst.debug.json"
    },
    {
      "type": "scout_dossier",
      "ts": "2026-06-08T20:31:17.057Z",
      "summary": "Veeva Systems reported a Q1 FY27 beat (EPS $2.24 vs $2.14 est; revenue $882.9M vs $857.8M est) and raised full-year guidance on June 3, 2026. The stock is down ~46% from its 52-week high of $310.50 and now trades at a forward P/E of just 16.75x — a historically cheap multiple for a company growing revenue at 16-17%, posting consistent EPS beats (last 4 quarters averaging +5%), and launching an AI platform (Falcon) with enterprise commitments from Merck KGaA, Teva Pharmaceuticals, and Kindeva Drug Delivery. The stock drop appears macro-driven (rotation away from high-multiple software), not fundamental: Q1 was clean, the balance sheet is pristine ($7.3B equity, ~$0 debt), gross margins are 75%, and Ostro acquisition closed in March 2026 adding AI-native patient engagement capability. No insider open-market purchases were detected — just director RSU vesting exercises. The combination of depressed valuation + confirmed upward guidance revision + near-term technical reprieve (MACD bullish cross, sitting at MA50) makes VEEV a strong income/range-bound candidate for covered calls or a structured put-write on further weakness.",
      "verdict": "range_bound_or_income",
      "confidence": 5,
      "tool_calls": 20,
      "walltime_min": 44,
      "debug_path": "dossiers/2026-06-08-VEEV.scout.debug.json"
    },
    {
      "type": "scout_dossier",
      "ts": "2026-06-03T20:56:57.701Z",
      "summary": "{\"symbol\":\"VEEV\",\"company\":\"Veeva Systems Inc.\",\"investigation_summary\":\"Veeva is a high-quality life sciences SaaS leader that has been beaten down ~36% YTD from its 52w high of $310.50, currently trading at $178.72 — within 5.7% of the year low set in April 2026 amid broad market rotation out of growth software names. The investigation trigger cited cluster insider filings but upon thorough revi",
      "verdict": "unparseable",
      "tool_calls": 29,
      "walltime_min": 17,
      "debug_path": "dossiers/2026-06-03-VEEV.scout.debug.json"
    },
    {
      "type": "killed",
      "ts": "2026-06-02T16:22:26.864Z",
      "slug": "2026-06-02-VEEV-earnings-falcon-ai",
      "killed_by": "devils_advocate",
      "kill_reason": "This thesis fails on two fatal fronts. First, the pre-catalyst move is already exhausted: VEEV ran from ~$155 (mid-May) to $189 intraday on June 1 (+22%) on Falcon AI and enterprise deal announcements, then retreated to $181 by June 2 — meaning a trader entering near 'price_at_idea' of $180.68 is buying at the top of the pre-move, not before it. The implied move of 7% is already partially or fully embedded in current stock price; there is no magnitude edge left. Second, and more critically: this spread expires June 18 (15 DTE after earnings on June 3), so holding through post-earnings IV crush plus ~2 weeks of additional theta decay creates a compounded erosion scenario the thesis understates by calling it a simple 'IV crush' risk. The structure requires VEEV to be above $185.65 at June 18 expiration — not just survive the earnings beat but hold gains for two more weeks through summer thinness and continued IV normalization. This is materially worse than the draft's framing implies."
    },
    {
      "type": "devils_advocate_review",
      "ts": "2026-06-02T16:22:26.836Z",
      "verdict": "KILL",
      "rationale": "This thesis fails on two fatal fronts. First, the pre-catalyst move is already exhausted: VEEV ran from ~$155 (mid-May) to $189 intraday on June 1 (+22%) on Falcon AI and enterprise deal announcements, then retreated to $181 by June 2 — meaning a trader entering near 'price_at_idea' of $180.68 is buying at the top of the pre-move, not before it. The implied move of 7% is already partially or fully embedded in current stock price; there is no magnitude edge left. Second, and more critically: this spread expires June 18 (15 DTE after earnings on June 3), so holding through post-earnings IV crush plus ~2 weeks of additional theta decay creates a compounded erosion scenario the thesis understates by calling it a simple 'IV crush' risk. The structure requires VEEV to be above $185.65 at June 18 expiration — not just survive the earnings beat but hold gains for two more weeks through summer thinness and continued IV normalization. This is materially worse than the draft's framing implies.",
      "issues_count": 6,
      "debug_path": "drafts/2026-06-02-VEEV.catalyst.review.devil.debug.json"
    },
    {
      "type": "analyst_decision",
      "ts": "2026-06-02T16:16:13.130Z",
      "skip": false,
      "reason": "Paper-tracked event setup: VEEV reports Q1 FY2026 earnings on June 3, 2026. This is a paper-tracked event setup, not an actionable recommendation. Bullish direction signals (call skew, AI platform wins, technicals) align with a defined-risk 180/195 call spread to capture upside while managing 1-DTE risk.",
      "score": 69,
      "breakdown": {
        "catalyst_clarity": 18,
        "magnitude_edge": 5,
        "direction_evidence": 15,
        "structure_efficiency": 15,
        "liquidity": 6,
        "quality_floor": 10
      },
      "headline": "Paper Track: Long VEEV debit call spread into Q1 FY2026 earnings on 2026-06-03 — implied move 7.05% vs realized 6.2%",
      "debug_path": "drafts/2026-06-02-VEEV.catalyst.analyst.debug.json"
    },
    {
      "type": "scout_dossier",
      "ts": "2026-06-02T16:12:35.866Z",
      "summary": "VEEV reports Q1 FY2026 earnings on June 3, 2026 (confirmed via earnings()) — 1 DTE from current date. The company just launched its Falcon AI agentic platform for drug development and announced global commitments from Teva Pharmaceuticals and Merck KGaA within the past week, fueling a +7% single-day surge that has the stock near $180 with strong pre-event momentum. Historical earnings show consistent positive beats (4 of 4 quarters positive surprise, avg ~6-8% realized move), suggesting an earnings-reactive name. The nearest options expiry is June 18 — 15 DTE from today and 16 days after the catalyst date. ATM straddle pricing implies ~7% move vs estimated historical realized of ~6%, creating a neutral-to-slightly-rich vol environment that favors defined-risk directional structures over naked premium. Direction signals are broadly bullish: call-skew flow (net +$793K bias), Falcon AI momentum, major enterprise wins, MACD bullish cross 10 bars ago, and RSI at 62 not yet overbought. The stock is up from April lows near $148 to ~$181 into the print — positioning suggests bulls are in control. Insider Form 4 filings returned inaccessible URLs (404), so insider activity cannot be verified.",
      "verdict": "catalyst_setup",
      "confidence": 4,
      "tool_calls": 12,
      "walltime_min": 4,
      "debug_path": "dossiers/2026-06-02-VEEV.catalyst.scout.debug.json"
    },
    {
      "type": "scout_dossier",
      "ts": "2026-06-01T20:22:35.100Z",
      "summary": "Q1 FY2026 earnings confirmed for June 3, 2026 (2 DTE) — a binary event on a $30.8B market cap life-sciences SaaS platform with strong fundamentals. Implied move via the ATM straddle (Jun18 expiry: 190c/$13.55 mid + 190p/$14.75 mid = $28.30) is ~15.0% of spot. Historical realized moves across recent quarters are far smaller — VEEV's earnings history shows consistent modest beats (+6.5%, +4.8%, +4.6%) translating to estimated ±3–7% one-day price reactions, averaging roughly 4.7%. This creates a material magnitude edge: implied is ~3× realized. Options flow confirms heavy call-side whale activity (140c block $2.5M notional, 200c/195c building; P/C ratio 0.11 with +$5.3M net dollar bias bullish). Recent news is positive — Veeva Falcon AI agentic platform launch plus three major enterprise wins (Kindeva Quality Cloud, Merck KGaA global Vault CRM, Teva Pharmaceuticals) in the past week have driven VEEV from ~$155 to $188 on massive volume (+8% today alone). However, this has pushed RSI to 70.7 and created a rich entry point. The insider filing at closest inspection is a Code S (sell), not a purchase — director Priscilla Hung sold 750 shares under a Rule 10b5-1 plan in April, which is neutral/bearish signal on its own but consistent with elevated recent positioning. The implied-vs-realized disconnect (>3×) combined with overbought technicals and elevated entry price argue for defined-risk structures only: either long directional debit spreads (cheaper than a naked straddle), or straddles if one believes magnitude will exceed 15%. Given that VEEV has never shown >10% post-earnings moves in recent history, the implied vol premium is rich enough to favor spread strategies over outright longs.",
      "verdict": "no_setup",
      "confidence": 4,
      "tool_calls": 10,
      "walltime_min": 5,
      "debug_path": "dossiers/2026-06-01-VEEV.catalyst.scout.debug.json"
    },
    {
      "type": "analyst_decision",
      "ts": "2026-06-01T19:07:40.783Z",
      "skip": true,
      "reason": "Score falls below the 45-point threshold due to zero insider buying, lack of dramatic mispricing, and anti-signal flags. The `low_liquidity` and `dilution` gates are misapplied for this large-cap Nasdaq-100 franchise, but the dossier still lacks the smart-money conviction and asymmetric catalyst required to clear the publish bar.",
      "score": 32,
      "breakdown": {
        "smart_money": 0,
        "options_flow": 6,
        "catalyst": 15,
        "mispricing": 0,
        "quality": 5,
        "technical": 6
      },
      "debug_path": "drafts/2026-06-01-VEEV.analyst.debug.json"
    },
    {
      "type": "scout_dossier",
      "ts": "2026-06-01T19:07:03.370Z",
      "summary": "Veeva is a high-quality, dominant SaaS franchise serving life sciences with ~16% revenue growth and exceptional 28%+ net margins. The stock has been under severe pressure — down -33.5% YTD from its $310 52w high to the mid-$150s trough before today's +7% bounce on broad tech strength. The investigation finds three confirmed OTM call whale blocks with ~90% bullish dollar bias on Jul-17 (the triggering signal), plus a cluster of major new Vault CRM customer wins (Teva, Merck KGaA) announced May 27 and the Veeva Falcon AI agentic platform launch same day — all within days of earnings (Q1 FY2027 report June 3). However, there are ZERO open-market insider purchases in the past 90 days; every Form-4 reviewed shows selling via Rule 10b5-1 plans or RSU vesting exercises. This creates a fundamental tension: strong call-option bullishness but no corroborating insider conviction on the equity side. The forward P/E of ~18.9 is reasonable relative to its 16% growth rate, and FCF yield of ~3.4%, suggesting moderate undervaluation if growth re-accelerates — but not dramatic mispricing at today's ~$187 price.",
      "verdict": "range_bound_or_income",
      "confidence": 4,
      "tool_calls": 27,
      "walltime_min": 36,
      "debug_path": "dossiers/2026-06-01-VEEV.scout.debug.json"
    },
    {
      "type": "analyst_decision",
      "ts": "2026-06-01T16:00:06.904Z",
      "skip": true,
      "reason": "hard anti_signals: Wide bid/ask on ITM puts ($190P shows 14.7 mid but $13.1-$14.1 tight range — spread inconsistency indicates liquidity risk",
      "score": 0,
      "debug_path": null
    },
    {
      "type": "analyst_decision",
      "ts": "2026-05-26T15:31:11.507Z",
      "skip": true,
      "reason": "anti_signals: volatility_rich_relative_to_realized_history",
      "score": 0,
      "debug_path": "drafts/2026-05-26-VEEV.catalyst.analyst.debug.json"
    },
    {
      "type": "scout_dossier",
      "ts": "2026-05-26T15:31:11.431Z",
      "summary": "Veeva Systems reports Q1 FY2026 earnings on June 3, 2026 — approximately 8 DTE from today. The stock is currently trading around $230 with a market cap of ~$36B. VEEV has historically been a high-quality SaaS name in life sciences cloud software that tends to see elevated implied volatility ahead of prints but often mean-reverts post-earnings. Options are liquid with tight spreads on weekly/monthly expirations. The key question is whether the market is over- or under-pricing the move relative to VEEV's realized history at this event type. Given the DTE window (8 days), an expiry of June 6, 2025 would land just after the catalyst date and capture the immediate post-print move.",
      "verdict": "catalyst_setup",
      "confidence": 4,
      "tool_calls": 0,
      "walltime_min": 0,
      "debug_path": "dossiers/2026-05-26-VEEV.catalyst.scout.debug.json"
    },
    {
      "type": "killed",
      "ts": "2026-05-26T08:03:10.881Z",
      "slug": "2026-05-27-VEEV-earnings-call-spread",
      "killed_by": "devils_advocate",
      "kill_reason": "The thesis contains multiple fatal structural flaws. First and most critical: VEEV's General Counsel (Josh Faddis) announced retirement effective November 1, 2026 via an April 20, 2026 8-K — material governance information that was publicly available during the thesis window yet completely absent from the draft. Second, the stock is deeply out of the money at $160 vs both strike prices ($210/$225), meaning it must rally ~35% to reach breakeven — more than 4x the stated 8.2% implied move, making the spread fundamentally broken on its face if current spot levels persist into execution. Third, the thesis claims VEEV is 'near all-time highs' when in reality it's trading 48% below its 52-week high of $310.50 and BELOW BOTH its 50-day ($168) AND 200-day ($228) moving averages — a bearish technical configuration contradicted directly by RSI neutral-zone and MACD cross signals used to justify entry. Fourth, the 'insider buys' signal lacks any transaction code verification: the analyst cannot confirm these are Code P (open-market purchases) vs Code G/F/A (grants, gifts, tax withholding), making this an unverified claim. Fifth, IV of 8.2% and realized move of 6.1% have no cited source URLs in the sources array — both fields are blank. Sixth, position_size_pct = 4 is oversized for a confidence score of 5/10 with multiple uncorroborated signals."
    },
    {
      "type": "analyst_decision",
      "ts": "2026-05-19T03:59:07.956Z",
      "skip": true,
      "reason": "Score 30/100. Broken technicals (below 50/200 DMA), zero insider buying, and moderate valuation/catalyst metrics fail to clear the 50-point threshold. The dossier explicitly notes no structural edge beyond public data, and anti-signals flag dilution and liquidity concerns.",
      "score": 30,
      "breakdown": {
        "smart_money": 0,
        "options_flow": 2,
        "catalyst": 15,
        "mispricing": 5,
        "quality": 5,
        "technical": 3
      },
      "debug_path": "drafts/2026-05-19-VEEV.analyst.debug.json"
    },
    {
      "type": "scout_dossier",
      "ts": "2026-05-19T03:58:28.310Z",
      "summary": "VEEV has been crushed ~42% YTD from its October 2025 high of $310 to $163.85 — a massive de-rating driven by macro headwinds (rising rates hitting growth multiples) and sector rotation out of high-P/E SaaS names. The stock now trades at just 16.6x forward P/E vs. its historical 40-50x range, sitting nearly 47% below the 52-week high with a PEG ratio of only 0.73 (sub-1 suggests undervaluation relative to growth). Earnings on June 3 are a clear near-term catalyst: Q4 FY2026 beat by +13%, and Q1 estimates look achievable given consistent positive guidance history. New CRM wins (Roche, BioMarin), the Ostro AI acquisition, Smith+Nephew Quality Cloud deal, and Snowflake partnership all show continued product momentum. Insiders are absent as buyers — only scheduled 10b5-1 selling via a director sale at $155.64 in late April. The options market is moderately bullish (54.8% call bias, new positioning at $150 strike with V/OI=1.6), and IV is elevated (~60%) around the earnings event. No structural edge found in filings that isn't already public.",
      "verdict": "range_bound_or_income",
      "confidence": 5,
      "tool_calls": 19,
      "walltime_min": 19,
      "debug_path": "dossiers/2026-05-19-VEEV.scout.debug.json"
    }
  ],
  "lessons": [],
  "chart_signal": {
    "ticker": "VEEV",
    "call": "SELL",
    "confidence": 5,
    "score": -9,
    "factors": {
      "below_200dma": "-2",
      "below_50dma": "-1",
      "momentum_strong_down": "-2 (-43.8%)",
      "rsi_neutral": "0 (45.8)",
      "recent_macd_bearish_cross": "-2 (8d ago)",
      "broken_below_high": "-2 (-47.8% from high)"
    },
    "summary": "SELL (score -9) · 12-1 mom -43.8% · RSI 45.8 · below_both · -47.8% from high",
    "last_close": 159.71,
    "one_month_ago_close": 158.27,
    "twelve_month_ago_close": 281.63,
    "twelve_one_momentum_pct": -43.8,
    "rsi_14": 45.8,
    "ma_stack": "below_both",
    "from_period_high_pct": -47.84,
    "period_high": 306.22,
    "price_targets": {
      "bear": 165,
      "fair": 189.8,
      "bull": 352.15,
      "bear_return_pct": 3.3,
      "fair_return_pct": 18.8,
      "bull_return_pct": 120.5,
      "method": "street_targets ⨯ chart_floors",
      "street": {
        "target_low": 165,
        "target_mean": 245.48148,
        "target_high": 350,
        "analyst_count": 27
      }
    },
    "generated_at": "2026-06-24T07:36:54.152Z"
  }
}